MRNA combination therapy for the treatment of cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10335486
APP PUB NO 20180369374A1
SERIAL NO

15996146

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • MODERNATX, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bai, Ailin Newton, US 32 251
Benenato, Kerry Sudbury, US 54 807
Frederick, Joshua P Boston, US 22 301
Hewitt, Susannah Jamaica Plain, US 18 147
Hoge, Stephen G Brookline, US 45 1892
Kumarasinghe, Ellalahewage Sathyajith Harvard, US 49 756
McFadyen, Iain Arlington, US 42 682
Presnyak, Vladimir Cambridge, US 67 802

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 2, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 2, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00